Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) insider Jason Hoitt sold 1,781 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $33.01, for a total value of $58,790.81. Following the completion of the transaction, the insider directly owned 12,207 shares of the company’s stock, valued at approximately $402,953.07. This trade represents a 12.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Jason Hoitt also recently made the following trade(s):
- On Wednesday, March 18th, Jason Hoitt sold 1,931 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.34, for a total value of $60,517.54.
Stoke Therapeutics Trading Up 3.7%
NASDAQ STOK opened at $34.41 on Friday. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $40.22. The stock has a market cap of $2.04 billion, a PE ratio of 51.46 and a beta of 1.07. The stock’s 50 day moving average is $32.60 and its 200 day moving average is $29.93.
Key Stoke Therapeutics News
- Positive Sentiment: Several firms reaffirmed or raised bullish views and price targets on STOK, supporting buying interest — Chardan reiterated a “Buy” rating. Chardan Capital Reiterates “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)
- Positive Sentiment: BTIG reaffirmed a Buy rating and set a $39 price target, signaling notable upside vs. recent levels and likely attracting momentum buyers. BTIG Research reaffirmation (Benzinga)
- Positive Sentiment: Wedbush raised its price target to $38 and Needham published a bullish outlook for strong price appreciation—additional analyst support that can underpin the rally. Wedbush Boosts Stoke Therapeutics (NASDAQ:STOK) Price Target to $38.00
- Positive Sentiment: Coverage of Stoke’s experimental program highlights broader clinical potential beyond seizure control — reporting suggests the drug aims to reverse developmental loss in Dravet syndrome, which supports longer‑term value. Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome
- Neutral Sentiment: Analysis pieces examined a recent sharp pullback and the drivers behind it — useful context for traders but not new company-specific catalyst. Stoke Therapeutics (NASDAQ:STOK) What Triggered This Sudden Drop?
- Negative Sentiment: Multiple insiders (including the CFO, general counsel and other executives) disclosed sizable sales across March 17–19, trimming positions by double-digit percentages — insider selling can weigh on sentiment and prompt investor caution. Representative filing: SEC Form 4 (Jonathan Allan)
Institutional Investors Weigh In On Stoke Therapeutics
Several large investors have recently bought and sold shares of STOK. Kestra Advisory Services LLC purchased a new stake in Stoke Therapeutics during the fourth quarter valued at $26,000. Harbour Investments Inc. grew its stake in shares of Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after buying an additional 898 shares in the last quarter. Generali Investments Management Co LLC purchased a new position in shares of Stoke Therapeutics in the 3rd quarter worth $41,000. BNP Paribas Financial Markets increased its holdings in shares of Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after buying an additional 1,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares in the last quarter.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on the stock. Guggenheim initiated coverage on shares of Stoke Therapeutics in a research report on Thursday, February 5th. They set a “buy” rating and a $60.00 target price for the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th. UBS Group set a $50.00 price target on shares of Stoke Therapeutics in a research note on Monday, December 15th. Wolfe Research assumed coverage on shares of Stoke Therapeutics in a report on Monday, February 23rd. They set an “outperform” rating and a $40.00 price objective for the company. Finally, Needham & Company LLC raised their price objective on Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $39.83.
About Stoke Therapeutics
Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.
The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.
See Also
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
